MALAT1 Is Associated with Poor Response to Oxaliplatin-Based Chemotherapy in Colorectal Cancer Patients and Promotes Chemoresistance through EZH2

In conclusion, this study illuminates the prognostic role of lncRNA MALAT1 in colorectal cancer patients receiving oxaliplatin-based treatment and further demonstrates how lncRNA MALAT1 confers a chemoresistant function in colorectal cancer. Thus, lncRNA MALAT1 may serve as a promising prognostic and therapeutic target for colorectal cancer patients. Mol Cancer Ther; 16(4); 739–51. ©2017 AACR.

Source: Molecular Cancer Therapeutics - April 2, 2017 Category: Cancer & Oncology Authors: Li, P., Zhang, X., Wang, H., Wang, L., Liu, T., Du, L., Yang, Y., Wang, C. Tags: Companion Diagnostics and Cancer Biomarkers Source Type: research